Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

Authors: Michael K. Lo, Friederike Feldmann, Joy M. Gary, Robert Jordan, *Roy Bannister, Jacqueline Cronin, Nishi R. Patel, John D. Klena, Stuart T. Nichol, Tomas Cihlar, Sherif R. Zaki, Heinz Feldmann, Christina F. Spiropoulou, Emmie de Wit

Year: 2019

Journal: Sci Transl Med

DOI: 10.1126/scitranslmed.aau9242

Summary

The paper tests the efficacy of remdesivir (GS-5734), a broad-acting antiviral nucleotide prodrug, against Nipah virus in African green monkeys. Remdesivir treatment resulted in the survival of all treated animals, while control animals succumbed to the infection.

Key Findings

Remdesivir protected African green monkeys from a lethal dose of Nipah virus
All treated animals survived the lethal challenge, whereas all control animals died
Mild respiratory signs were observed in two of four treated animals

Methodology

Study Type: Experimental/Animal Study
Sample Size: 4 African green monkeys (treated) and control group size not specified
Geographic Focus: Not specified
Time Period: 24 hours after inoculation for 12 days

Topics

Virology, Therapeutics

Relevance

The study suggests remdesivir as a promising antiviral treatment for Nipah virus infection

Source

View the entire paper: File:Nihms-1047526.pdf